hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare‐Based Study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Beyond the controlled setting of trials, scarce information exists on the burden, predictors, and outcomes associated with elevated hs CRP (high‐sensitivity C‐reactive protein) in “real‐world” patients with myocardial infarction ( MI ). Methods and Results: We included all‐coming MI survivors undergoing hs CRP testing >30 days after an MI during routine health care in Stockholm, Sweden (2006–2011). hs CRP tests measured during hospitalization/emergency department visits, followed by antibiotics or indicative of acute illness, were excluded, together with patients with ongoing/recent cancer, chronic infections, or immunosuppression. Inflammation was defined over a 3‐month baseline window and associated with subsequent death and major adverse cardiovascular events (composite of MI, ischemic stroke, or cardiovascular death). Included were 17 464 patients (63% men; mean age, 72.6 years) with a median hs CRP level of 2.2 (interquartile range, 1.0–6.0) mg/L and a median of 2.2 (interquartile range, 0.8–4.9) years since their MI . Most (66%) had hs CRP ≥2 mg/L, and 40% had hs CRP >3 mg/L. Lower hemoglobin, lower estimated glomerular filtration rate, and comorbidities (eg, heart failure, peripheral vascular disease, stroke, atrial fibrillation, diabetes mellitus, and rheumatoid diseases) were associated with higher odds of hs CRP ≥2 mg/L. Conversely, previous percutaneous coronary intervention, ongoing renin‐angiotensin blockade, and statins were associated with lower hs CRP ≥2 mg/L odds. Patients with hs CRP ≥2 mg/L were at higher risk of major adverse cardiovascular events (n=3900; adjusted hazard ratio, 1.28; 95% CI, 1.18–1.38) and death (n=4138; adjusted hazard ratio, 1.42; 95% CI, 1.31–1.53). Results were robust across subgroups of patients and after exclusion of events occurring during the first 6 to 12 months. On a continuous scale, the association between hs CRP and outcomes was linear until hs CRP >5 mg/L, plateauing thereafter. Conclusions: Most patients with MI exhibit elevated hs CRP levels. Besides identifying populations at high‐inflammatory risk, this study extends the prognostic validity of this biomarker from trial evidence to real‐world healthcare settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“The CANTOS (Canakinumab AntiInflammatory Thrombosis Outcome Study) convincingly showed that, among patients with prior myocardial infarction (MI) and hsCRP ≥2 mg/L, treatment with a monoclonal antibody targeting interleukin-1b was associated with fewer cardiovascular events.(7) The demonstration that low-dose From the…”
ResultOrigin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055 · cited 1×
“Comorbidities identified in this study used established algorithms with an 85% to 95% validity.(16) We collected information on coronary artery bypass grafting and percutaneous coronary intervention (PCI) by identification of issued Nordic Medico-Statistical Committee surgical procedure codes (Table S1).”
MethodActivation and regulation of the inflammasomes
Latz, E., Xiao, T. S., & Stutz, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3452 · Cited by 2,884 · cited 1×
“inflammasome that leads to interleukin-1b activation.(31) We also found that the risk of inflammation was lower among users of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker.”
BackgroundInflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Inflammatory mechanisms in patients with chronic obstructive pulmonary disease
Barnes, P. J. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.011 · Cited by 1,683
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Lindahl, B., Toss, H., Siegbahn, A., Venge, P., & Wallentin, L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431602 · Cited by 1,224
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919 · cited 2×
“Such speculation is in line with results from CANTOS, whereby individuals most likely to achieve the target hsCRP concentration of <2 mg/L at 3 months were, naturally, those who started out with lower baseline values.(23) Those who started out with higher baseline values and did not reach the target had only small and…”
BackgroundResultElevation of C-reactive protein in “active” coronary artery disease
Berk, B. C., Weintraub, W. S., & Alexander, R. W. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90079-g · Cited by 588
Kleveland, O., Kunszt, G., Bratlie, M., Ueland, T., Broch, K., Holte, E., Michelsen, A. E., Bendz, B., Amundsen, B. H., Espevik, T., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw171 · Cited by 400
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.649939 · Cited by 385
Martínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Koenig, W., Libby, P., Everett, B. M., Lefkowitz, M., Thuren, T., & Cornel, J. H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.490 · Cited by 297
Held, C., White, H. D., Stewart, R. A. H., Budaj, A., Cannon, C. P., Hochman, J. S., Koenig, W., Siegbahn, A., Steg, P. G., Soffer, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005077 · Cited by 291
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0124-5 · Cited by 256
Schieffer, B., Bünte, C., Witte, J., Hoeper, K., Böger, R. H., Schwedhelm, E., & Drexler, H. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.065 · Cited by 239
Fraenkel, P. G. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.09.005 · Cited by 192 · cited 1×
“Suppression of erythropoiesis by inflammation, together with alterations of the erythrocyte membrane that impair its survival and impaired iron homeostasis, is thought to cause anemia of inflammation in a wide range of chronic diseases.(27) Although inflammation is prevalent in people with advanced kidney disease,(28)…”
BackgroundClinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 174
Kalkman, D. N., Aquino, M. B., Claessen, B. E. P. M., Baber, U., Guedeney, P., Sorrentino, S., Vogel, B., de Winter, R. J., Sweeny, J. M., Kovacic, J. C., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy633 · Cited by 166 · cited 2×
“The chief finding in our study is the consistent association between hsCRP and MACEs or risk of death, expanding to routine health care the observations from clinical trials4–6 and patients undergoing PCI.22 Another addition to the literature is our spline analyses, showing on a continuous scale the dynamic outcome as…”
ResultImmunologic Effects of the Renin-Angiotensin System
Crowley, S. D., & Rudemiller, N. P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101066 · Cited by 153
Monitoring of inflammation in patients on dialysis: forewarned is forearmed
Meuwese, C. L., Stenvinkel, P., Dekker, F. W., & Carrero, J. J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.2 · Cited by 139 · cited 1×
“Although inflammation is prevalent in people with advanced kidney disease,(28) a wealth of evidence suggests that multiple processes related to renal injury and repair induce unique changes in innate and adaptive immunity.(28) It is, however, unknown if resolving inflammation may retard kidney disease progression.”
BackgroundSelf-citationDi Napoli, M., & Papa, F. (2003) · Stroke · doi:10.1161/01.str.0000099124.84425.bb · Cited by 122
Runesson, B., Gasparini, A., Qureshi, A. R., Norin, O., Evans, M., Barany, P., Wettermark, B., Elinder, C. G., & Carrero, J. J. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfv117 · Cited by 96 · cited 1×
“Because plasma creatinine is routinely ordered during the characterization and follow-up of patients with MI, the Stockholm Creatinine Measurements healthcare-use cohort was estimated to capture the virtually complete (99% coverage) population with MI of the region.(14) Laboratory data were linked with regional and na…”
MethodSelf-citationRidker, P. M., Köenig, W., Kastelein, J. J. P., Mach, F., & Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy723 · Cited by 87 · cited 1×
“As discussed in recent editorials, hsCRP remains often unmonitored in secondary cardiovascular prevention by internists and cardiologists.(36,37) The characterization of inflammation risk in our study, thus, serves to identify patient groups who may benefit from more aggressive and guideline-based treatment of risk fa…”
BackgroundTuñón, J., Bäck, M., Badimón, L., Bochaton‐Piallat, M., Cariou, B., Daemen, M. J. A. P., Egido, J., Evans, P. C., Francis, S., Ketelhuth, D. F. J., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318773384 · Cited by 75
Within-Person Variability in High-Sensitivity C-Reactive Protein
Bower, J. K., Lazo, M., Juraschek, S. P., & Selvin, E. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3712 · Cited by 72 · cited 1×
“At this point, we estimated intraindividual hsCRP variability in the year after the index date to evaluate if our coefficients of variation approximated to previous reports from controlled settings.(11,15)”
MethodRidker, P. M. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12862 · Cited by 49 · cited 1×
“methotrexate in patients with MI failed to reduce levels of interleukin-1b, interleukin-6, or hsCRP and did not result in fewer cardiovascular events than placebo(8) points perhaps future pharmacologic attention away from broad-spectrum anti-inflammatory treatments and toward targeted inhibition of the interleukin-1/i…”
BackgroundTsikouris, J. P., Suarez, J. A., Simoni, J. S., et al. (2004) · PubMed · Cited by 32
Pagidipati, N. J., Hellkamp, A. S., Sharma, P. P., Wang, T. Y., Fonarow, G. C., & Pencina, M. J. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.07.014 · Cited by 14 · cited 1×
“Our results are the largest healthcare-based analysis to date, and the external validity of the cross-sectional part of our study is supported by a recent report of 1296 participants from the US National Health and Nutrition Examination Survey that reaches similar prevalence figures.(21) Also, recently, Kalkman and co…”
Result
Cited by
Kraler, S., Libby, P., Evans, P. C., Akhmedov, A., Schmiady, M. O., Reinehr, M., Camici, G. G., & Lüscher, T. F. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316256 · Cited by 65
Metadata
- Authors
- Carrero, J. J., Andersson Franko, M., Obergfell, A., Gabrielsen, A., & Jernberg, T.
- Venue
- Journal of the American Heart Association
- Published
- 2019-06-04
- Volume
- 8
- Issue
- 11
- Pages
- e012638-e012638
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2946966338
- Cited by
- 161
- References
- 34
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.